Nav: Home

Elicio Therapeutics' Darrell Irvine co-authors research published in Science

July 11, 2019

  • Research conducted at the Irvine Lab at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology is being utilized in Elicio's AMP-CAR-T Platform

  • Activation of CAR-T cells with Amphiphiles delivered to the lymph nodes induces massive CAR-T expansion, substantially improved efficacy across cancer types, and durable cures for solid tumors
CAMBRIDGE MA., July 12, 2019 - Elicio Therapeutics, a next generation immuno-oncology company, engineering therapies for cancer killing immune responses, today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response. The research, conducted in the labs of Elicio co-founder, Darrell Irvine, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, was published on July 12 by the journal Science, in a paper entitled "Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor."1

Through precise targeting and delivery directly to the lymphatic system, Elicio is engineering potent Amphiphile immunotherapies including cell therapy activators, immunomodulators, and vaccines for an array of aggressive cancers. The Amphiphile approach is based on the ground-breaking work of Darrell Irvine, PhD., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. The company is currently utilizing the study findings in its AMP-CAR-T platform to develop therapeutic interventions that activate and amplify CAR-T therapy to combat an array of cancers including solid tumors. In addition to enhancing the magnitude and functionality of co-administered CAR-T cells, the published data further shows that the combination of CAR-T with AMP-CAR-T activators leads to the potent induction of natural immune responses thought to be critical for improving activity in solid tumors, enabling prolonged survival and durable cures where CAR-T alone has no effect. Elicio is developing the AMP-CAR-T platform for combination with CAR-T cell therapies in a variety of settings including those targeting CD19, BCMA, and several solid tumor indications.

"CAR-Ts show great promise but historically they've had issues with durability of response and efficacy beyond hematologic cancers, which we hypothesized could be due to the lack of a means to properly stimulate these cells in vivo," said Darrell Irvine, Elicio co-founder, senior scientific advisor, and a supporting author. "What we saw in this study is that by activating CAR-T cells through their chimeric receptor in the native micro-environment of lymph nodes, it's possible to enhance CAR-T treatment of solid tumors across cancer types."

"We believe that Elicio's AMP-CAR-T platform has the potential to solve many of the major obstacles CAR-T therapy is facing by activating CAR-T cells in the lymph nodes to amplify immune responses which could lead to durable cures for aggressive, liquid and solid tumors," said Julian Adams, Ph.D., board chair, Elicio. "Elicio is developing a pipeline of AMP-CAR-T activators which when administered with CAR-T cells, or other CAR-engineered immune cells, will amplify their function for patients, creating a more powerful and lasting immune response."
-end-
About the AMP-CAR-T platform

The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the "brain center" of the immune response, to significantly amplify and enhance the body's own system of defenses to defeat cancer, and stop its recurrence. When combined with CAR-T therapy, AMP-CAR-T activators specifically designed to bind to the CAR receptor are presented on the cell surface of immune cells in the lymph nodes. CAR-T cells passing through the lymph nodes en route to the tumor see these AMP-CAR-T activators on the surface of specialized antigen presenting cells (APCs), which then deliver potent activating signals to T cells to coordinate their expansion, development of anti-tumor functions, and mobilization against tumors. This strategy is highly flexible for universal application with any CAR-T therapy without the need for re-engineering of the CAR-T cell design.

About Elicio Therapeutics

Elicio, based in Cambridge MA, is committed to transforming the lives of patients and their families by re-engineering the body's immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, and vaccines for an array of aggressive cancers. Elicio's lead Amphiphile vaccine targeting KRAS-driven cancers will begin initial patient studies in pancreatic and colorectal cancer patients in the first half of 2020. These programs are followed by a broad preclinical pipeline of lymph node targeted immunotherapies. For more information please visit http://www.elicio.com.

[1] Leyuan Ma et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 2019;

Media Contact:

Liza Sullivan
lsullivan@denterlein.com
Mobile: 917-981-7494

Denterlein

Related Lymph Nodes Articles:

Delaying lymph node biopsy after melanoma diagnosis does not affect survival rates
Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn't adversely impact long-term clinical outcomes, according to new study findings published on the Journal of the American College of Surgeons website.
Zika virus persists in the central nervous system and lymph nodes of rhesus monkeys
Zika virus can persist in cerebrospinal fluid (CSF), lymph nodes and colorectal tissue of infected rhesus monkeys for weeks after the virus has been cleared from blood, urine and mucosal secretions, according to a study published online in Cell.
Some breast cancer patients on neoadjuvant chemo may avoid axillary lymph node dissection
Axillary lymph node dissection could be avoided by certain early-stage breast cancer patients receiving neoadjuvant chemotherapy.
Study says CT use OK for some colon cancers, yet challenging for lymph node involvement
CT has good sensitivity for the detection of colon cancers with tumors that have spread beyond the bowel wall, however, it remains a challenge in detecting nodal involvement, which could have considerable consequences given the increasing interest in neoadjuvant treatment for colon cancer.
Novel tracer safely and effectively maps sentinel lymph nodes in breast cancer patients
A recent study by researchers at Peking University Cancer Hospital & Institute demonstrates the effectiveness and safety of Tc-99m-rituximab, a new SLN radiotracer, that targets the antigen CD20, which is expressed extensively in lymph nodes.
In child heart patients, a novel approach improves symptoms of hazardous lymph blockage
Pediatric researchers have devised an innovative, safe and minimally invasive procedure that helps relieve rare but potentially life-threatening airway blockages occurring in children who had surgery for congenital heart defects.
Macrophages surrounding lymph nodes block the progression of melanoma, other cancers
Researchers at Massachusetts General Hospital have identified a type of immune cell that appears to block the progress of melanoma and other cancers in animal models.
Targeted axillary dissection of lymph nodes after chemotherapy improves staging accuracy of node-positive breast cancer
A new procedure developed by surgeons at The University of Texas MD Anderson Cancer Center improves the accuracy of axillary staging and pathologic evaluation in clinically node-positive breast cancer, and reduces the need for a more invasive procedure with debilitating complications.
Cornell engineers develop 'killer cells' to destroy cancer in lymph nodes
Cornell biomedical engineers have developed specialized white blood cells -- dubbed 'super natural killer cells' -- that seek out cancer cells in lymph nodes with only one purpose: destroy them.
Battery-free smart camera nodes automatically determine their own pose and location
Scientists at Disney Research and the University of Washington have shown that a network of energy-harvesting sensor nodes equipped with onboard cameras can automatically determine each camera's pose and location using optical cues.

Related Lymph Nodes Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".